Suchergebnisse - "Abacavir"

PubPharm (2.416)

31

Abacavir causes leukocyte/platelet crosstalk by activating neutrophil P2X7 receptors thus releasing soluble lectin-like oxidized low-density lipoprotein receptor-1

enthalten in: British journal of pharmacology | 2023

von Blanch-Ruíz, M. | Sánchez-López, A. | Ríos-Navarro, C. | +6

32

Methods optimization and application : Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment

enthalten in: Journal of pharmaceutical and biomedical analysis | 2023

von Ngwenya, N. | Mahlambi, P.

33

Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial : Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect

enthalten in: WHO International Clinical Trials Registry Platform | 2023

34

Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial : Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect

enthalten in: WHO International Clinical Trials Registry Platform | 2023

35

Comparing implications of cardiovascular risk of abacavir and integrase inhibitors : why scientific community is confused and timid?

enthalten in: AIDS (London, England) | 2023

von Guaraldi, G. | Milic, J.

36

Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline : A retrospective observational study

enthalten in: HIV medicine | 2023

von Hikasa, S. | Shimabukuro, S. | Hideta, K. | +6

37

Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing

enthalten in: Sensors (Basel, Switzerland) | 2023

von Pražáková, L. | Fischer, J. | Taylor, A. | +1

38

Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

enthalten in: AIDS (London, England) | 2023

von Jaschinski, N. | Greenberg, L. | Neesgaard, B. | +30

CommentIn: AIDS. 2023 Mar 1;37(3):541-543. - PMID 36695364

39

Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?

enthalten in: AIDS (London, England) | 2023

von Fichtenbaum, C. | Mallon, P.

CommentOn: AIDS. 2023 Mar 1;37(3):467-475. - PMID 36001525

40

AOP-Based Transformation of Abacavir in Different Environments : Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products

enthalten in: Molecules (Basel, Switzerland) | 2023

von Evgenidou, E. | Vasilopoulou, K. | Koronaiou, L. | +3